Quantcast
Channel: DailyFinance.com
Viewing all 9760 articles
Browse latest View live

3 Predictions for the New Week

$
0
0

Filed under:

I went out on a limb last week, and now it's time to see how that decision played out.

  • I predicted that Microsoft would close lower on the week. Steve Ballmer's surprising pending resignation led to a spike a week earlier, but it seemed overblown for a company that will struggle in the transformation from a software company to one that excels at products and services. Mr. Softy's stock took a 4% hit on the week. I was right.
  • I predicted that the tech-heavy Nasdaq would outperform the Dow Jones Industrial Average. . This has been a tricky call lately, so how did it play out this time? Well, this was a bad week for tech stocks. The Nasdaq moved 1.9% higher, and that was worse than the Dow's 1.3% slip. I was wrong.
  • My final call was for OmniVision Technologies to beat Wall Street's income estimates in its latest quarter. The maker of image sensors used in digital cameras, smartphones, and tablets has been cashing in on the popularity of portable computing gadgetry. It had also been posting blowout quarterly results over the past year. I was banking on seeing the trend continue. Analysts were looking for a profit of $0.43 a share during the quarter, and it came through with adjusted net income of $0.55. The stock fell on OmniVision's disappointing outlook, but it was still a beat looking back. I was right.

Two out of three? I can do better than that.

Let me once again whip out my trusty, dusty, and occasionally accurate crystal ball to make three calls that may play out over the next few trading days.


1. Tesla Motors will close lower on the week
Everything seems to go right for Elon Musk these days, and Tesla Motors shareholders are grateful. the maker of plug-in electric cars has seen its shares pop fivefold.

The future's bright for Tesla, but its $20.5 billion market cap seems a bit extreme for where it is in its life cycle. Against this backdrop, the market's showing plenty of volatility, making high-beta stocks vulnerable. Tesla has bucked the malaise so far. August was the market's worst month in more than a year, but Tesla had no problem moving higher. It hit a new high earlier this past week.

For a week, at least, Tesla's likely to be due for a breather. My first call is for this Wall Street darling to close lower on the week.

2.The Nasdaq Composite will beat the Dow this week
Tech has been a big winner in recent years, so betting on tech over stodgy blue chips has been a good bet for me more often than not.

I'm going to stick with this pick. Most of the names in the composite are just too cheap at this point, and tech should be what carries us through the economic recovery. Earnings reports were rough in some places this past season, but the long-term outlook is still quite favorable. The market is ripe for the tech-stacked secondary stocks to continue to outpace the 30 megacaps that make up the Dow Jones Industrial Average.

3. Bazaarvoice will beat Wall Street's earnings estimates
Some stocks are just flat-out better than others.

Bazaarvoice is a leading provider of social commerce solutions. More than 1,000 retailers lean on Bazaarvoice's data -- covering more than 400 million questions and experiences on roughly 20 million different products -- to drive sales, awareness, and customer loyalty.

Another thing it does is make analysts look like perpetual underachievers. If analysts say the company posted a loss of $0.08 a share in its latest quarter, I'll argue that it held up better than that. History's on my side!

One of my best tricks to beating the market is finding stocks that perpetually land ahead of the prognosticators. Let's go over the past year of earnings reports.

Quarter

EPS Estimate

EPS

Surprise

Q1 2013

($0.14)

($0.07)

50%

Q2 2013

($0.10)

($0.07)

30%

Q3 2013

($0.12)

($0.06)

50%

Q4 2013

($0.13)

($0.12)

8%

Source: Thomson Reuters.

Things can change, of course. Bazaarvoice isn't profitable, so the beats so far have merely resulted in its posting a smaller loss than Wall Street was expecting. New projects or hiring sprees can bump costs and deficits higher. This is also a competitive market, as tech companies armed with data try to reach out to businesses.

However, it's hard to argue against the trend. Everything seems to be falling into place for another market-thumping quarter on the bottom line.

Three for the road
Well, there are three predictions right there. Let's see how I fare this week.

I'm not the only one making predictions around here! The Motley Fool's chief investment officer has selected his No. 1 stock for this year. Find out which stock it is in the special free report: "The Motley Fool's Top Stock for 2013." Just click here to access the report and find out the name of this under-the-radar company.

The article 3 Predictions for the New Week originally appeared on Fool.com.

Longtime Fool contributor Rick Munarriz has no position in any stocks mentioned. The Motley Fool recommends Tesla Motors and owns shares of Microsoft and Tesla Motors. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments


Apple's Fantastic August Performance

$
0
0

Filed under:

August was a tough month for stocks -- unless you're talking about Apple , that is. The nation's second largest company by market capitalization outperformed the S&P 500 by an impressive 11.5%, ending the month behind only four other index components -- click here to see which stocks beat the storied iPhone maker last month.

AAPL Total Return Price Chart

To be fair, shares of Apple were primed for a superior performance. By the end of June, they had lost more than 40% from their September high of $705. They trade for 12 times earnings, which equates to a 31% discount to the S&P 500 overall. And they yield 2.5%, which beats the broader market's 2.12% yield by 18%.


On top of that, or perhaps because of it, the stock has recently caught the eye of at least one high-profile investor. Carl Icahn, the noted activist investor, announced earlier in the month that he had taken a $1.5 billion stake in the company. His thesis is simple: Apple is undervalued and has the resources to execute an even larger capital return than the $100 billion program announced in April.

"Buy the company here and even without earnings growth, we think it ought to be worth $625," Icahn said in an interview with The Wall Street Journal.

Just this past week, moreover, Icahn went to Twitter to announce that he and Apple CEO Tim Cook will be having dinner soon to discuss both the magnitude and timing of the company's buyback. And while some people are equating Icahn's move as a meddlesome analogy to his position in Dell, as my colleague Adam Levin-Weinberg noted, his "activism poses no credible danger at all."

It's worth observing here that Apple's performance last month wasn't wholly the result of external factors. In the first case, the rumors continue to circulate that a new product line is in the mix. On Wednesday, for example, the Apple blog AppleInsider reported that the Cupertino-based company "is rumored to be gearing up to partner with Inventec in 2014 to manufacture a massive 63.4 million smart watches priced at $199."

In addition, it's widely assumed that Apple has chosen Sept. 10 to announce the release of its latest iPhone, the 5S, in addition to a cheaper version, the 5C, that's presumably geared toward consumers in emerging markets. The hope is that the move puts Apple a step closer to locking up a deal with China Mobile, the world's largest mobile network which for now remains off-limits to Apple's wares.

For Apple's stock to soar, a few critical things need to fall into place. In The Motley Fool's special free report "5 Secrets to Apple's Future," we outline the key factors every Apple investor needs to watch. Just click here now for your free report.

The article Apple's Fantastic August Performance originally appeared on Fool.com.

John Maxfield owns shares of Apple. The Motley Fool recommends and owns shares of Apple. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Will This High-Tech Tool Annoy GM's Customers?

$
0
0

Filed under:

Even as the new Chevy Silverado impresses customers, Chevy's customer-satisfaction scores remain low. Photo credit: General Motors.

General Motors is facing an interesting challenge. On one hand, its product line is arguably better than it has ever been -- and it's continuing to improve rapidly. On the other hand, sales and profits still aren't as strong as GM would like -- and recent customer satisfaction ratings on GM brands like Chevrolet have been among the worst in the industry.


In the midst of this, GM is funding a new initiative for its dealers: Web-tracking software that is said to help dealers pull more customers in the door. Is that likely to help, or hurt? In this video, Fool contributor John Rosevear looks at this initiative, and at whether it will improve the sales process for customers -- or just make them even more wary of car-dealer tactics.

GM's turnaround is still a work in progress, but Ford's is already rewarding shareholders. But for Ford's stock to really soar, a few more critical things need to fall into place. In The Motley Fool's special free report titled "5 Secrets to Ford's Future," we outline the key factors every Ford investor needs to watch. Just click here now for your free report.

The article Will This High-Tech Tool Annoy GM's Customers? originally appeared on Fool.com.

Fool contributor John Rosevear owns shares of General Motors. The Motley Fool recommends General Motors. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

A Key Android Leader Leaves for the "Apple of China"

$
0
0

Filed under:

One of the under-appreciated reasons great technology companies fall is that once they hit a certain size, talented employees who have risen through the company's ranks begin leaving for younger, more dynamic companies with longer runways for growth. 

While Google (Nasdaq: GOOG) still ranks atop many lists for best employers, its size-and the inherent bureaucracy that comes along with it-is a major challenge to keeping talent. The most recent illustration of this is that Hugo Barra is leaving the company to join Chinese smartphone upstart Xiaomi. His exit comes just six months after Android chief Andy Rubin left the company. 

While there might have been unique personnel issues behind Barra's departure (reports cited a recent break-up with an employee now dating Google co-founder Sergey Brin), his departure to a Chinese start-up is interesting on its own. Yet, it becomes even more fascinating when you consider Xiaomi heavily forks Android, ripping out key Google services like its app store. 


Xiaomi is definitely a fascinating company, data from smartphone research companies showed it outselling Apple (Nasdaq: AAPL) last quarter. To hear more about the troubles of big tech companies retaining talent and why Barra might be interested in moving on to a company many call the "Apple of China," watch the video below. 

The tech world has been thrown into chaos as the biggest titans invade one another's turf. At stake is the future of a trillion-dollar revolution: mobile. To find out which of these giants is set to dominate the next decade, we've created a free report called "Who Will Win the War Between the 5 Biggest Tech Stocks?" Inside, you'll find out which companies are set to dominate and give in-the-know investors an edge. To grab a copy of this report, simply click here -- it's free!


The article A Key Android Leader Leaves for the "Apple of China" originally appeared on Fool.com.

Eric Bleeker, CFA has no position in any stocks mentioned. Jamal Carnette owns shares of Apple. Simon Erickson owns shares of Apple. The Motley Fool recommends Apple and Google. The Motley Fool owns shares of Apple and Google. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

5 Stocks Growing Their Dividends by More Than 10% Per Year

$
0
0

Filed under:

Dividend investors would be wise to focus not just on a stock's current yield, but also on the long-term growth potential of its dividends. That's because strong businesses that consistently raise their dividend payouts reward shareholders with a steadily rising income stream that essentially equates to a raise every year. And, well, who doesn't like a raise?

But there are other reasons to value dividend growth so highly, and they're well supported by research. For instance, a study by C. Thomas Howard published in Advisor Perspectives found that for every percentage point a stock's yield rises, its annual return increases by 0.22 percentage points if it's a large cap, 0.25 if it's a mid cap, and 0.46 if it's a small cap. Even better, Howard found that dividend-growing stocks outperformed dividend cutters by 10 percentage points per year from 1973 to 2010 and beat both flat- and no-dividend stocks. And the icing on the cake is that Howard showed that this outperformance came with a third less volatility. Higher returns, less volatility-induced stress, and a steadily growing income stream -- what's not to love?

With that in mind, here are five stocks that have grown their dividends by more than 10% over the past year.

Company

1-Year Dividend Growth Rate

Ecolab

14.8%

Fastenal

14.8%

CSX

14%

Huntsman

12.5%

Teck Resources

12.5%


Source: S&P Capital IQ.

Ecolab provides cleaning and related products and services to the hospitality, food-service, health-care, and industrial markets. CAPS participants have awarded Ecolab with a top five-star rating, and the company is paying out a growing 1% dividend.

Fastenal operates as a wholesaler and retailer of industrial and construction supplies. Its product lineup includes fastener products such as bolts, nuts, screws, studs, and related washers; and miscellaneous supplies and hardware consisting of various pins and machinery keys, concrete anchors, metal framing systems, wire ropes, strut products, rivets, and related accessories. Fastenal currently has a four-star ranking on CAPS and offers investors a 2.2% yield.

CSX provides rail, intermodal, and rail-to-truck services that together help to make it one of the leading transportation companies in the United States. Fools appreciate the wide competitive moat surrounding CSX's rail network -- as well as its rising 2.4% dividend -- and have given it a top five-star rating in CAPS.

Huntsman is a global manufacturer of organic and inorganic chemical products including polyurethane chemicals, epoxy resin compounds and formulations, textile chemicals and dyes, and titanium dioxide. Huntsman sports a four-star rating in CAPS and is yielding 2.8%.

Teck Resources engages in the exploration, acquisition, and production of natural resources, including copper, steelmaking coal, gold, silver, and specialty metals. In addition, it holds ownership interests in oil sands projects in the Athabasca region of Alberta. Teck Resources has a four-star CAPS rating and offers investors a 3.4% dividend.

The Foolish bottom line
Had you invested in these companies a year ago, you would have enjoyed total dividend increases ranging from 12% to nearly 15%. That level of growth would provide a substantial boost to just about any investor's dividend income. But more important to investors today is to identify the companies that will grow their dividends substantially in the years ahead. If you're interested in hearing about some excellent companies that are likely to boost their dividends from this point forward, I'd like to offer you a brand-new free report from The Motley Fool's expert analysts called "Secure Your Future With 9 Rock-Solid Dividend Stocks." Today I invite you to download it at no cost to you. To discover the identities of these companies before the rest of the market catches on, you can access this valuable free report by simply clicking here now.

The article 5 Stocks Growing Their Dividends by More Than 10% Per Year originally appeared on Fool.com.

Joe Tenebruso manages a Real-Money Portfolio for The Motley Fool and is an analyst on the Fool's Stock Advisor and Supernova premium service teams. You can connect with him on TwitterL @Tier1Investor. Joe has no position in any stocks mentioned. The Motley Fool owns shares of CSX and Ecolab. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

The Future of Natural Gas in 2 Slides

$
0
0

Filed under:

Oil and natural gas producer Vanguard Natural Resources likes to go against the grain. While most of its peers have been focused on acquiring or developing oil-rich assets, Vanguard has been shopping in the clearance isle and stocking up on natural gas. It's a move that could pay off handsomely in a couple of years as the supply and demand balance for natural gas begins to shift.

Vanguard's business model is pretty simple. It buys up oil and gas reserves and then locks in the margins of the future production by hedging it for the long term. In its most recent natural gas acquisitions, the company was able to pick up dirt cheap assets that will earn a fair profit on the production over the next few years. However, over the longer term, those assets could turn out to be a real gem as the supply and demand imbalance for natural gas begins to shift. The following slide breaks down those fundamentals:


Source: Vanguard Natural Resources Investor Presentation (link opens a PDF).

Clearly, the biggest demand driver will come from already approved natural gas export terminals such as Cheniere Energy's Sabine Pass. These projects will sop up a big portion of the increase in natural gas production over the next few years. As the slide shows, by 2018 we should be exporting about 5.6 billion cubic feet of natural gas per day, or Bcf/d. For some perspective, as of this past May, natural gas production in the contiguous 48 states was 73.37 Bcf/d, meaning these future approved exports would equate to less than 8% of current production.

Another major future demand driver will come from transportation, where gas-to-liquids and compressed natural gas, or CNG are expected to sop up another 3.1 Bcf/d of incremental demand. Driving this demand, at least on the CNG side, is Clean Energy Fuels , which is building America's Natural Gas Highway. What should be noted, though, is that Clean Energy has a lot more potential outside the CNG market. While CNG has the potential to displace 5.5 billion gallons of fuel per year in transit buses and garbage trucks, the bigger market is the LNG potential for the long-haul truck market, which is a 25 billion-gallon-a-year market. If Clean Energy can make inroads into that market, it could add significant demand for natural gas in the coming years that's not reflected on the next chart.

Source: Vanguard Natural Resources.

This potential imbalance is good news for natural gas producers, like the nation's No. 2 producer, Chesapeake Energy , as well as other natural gas heavy producers like SandRidge Energy . While both companies are focused on growing oil and natural gas liquids production, as the supply and demand dynamics shift over time, it should lead to higher prices.

Chesapeake currently produces about 3.1 Bcf/d of natural gas, which is nowhere near as profitable as the oil and NGLs it produces. However, for some perspective, Chesapeake could earn 10% more money this year if gas stays above $5 for the rest of the year. It's a similar story for SandRidge. In its case, 55% of its Mississippian Lime production is natural gas, yet the company derives 80% of its revenue from the 45% of its production that's oil-focused. Bottom line: Higher natural gas prices means higher revenue and earnings for both companies.

All this is not to say that Americans should expect a natural gas price spike leading up to 2018. On the contrary, as the price rises, so should production. Several natural gas basins are currently not economical, but they would be if the price of natural gas rose to between $5 and $6 per Mcf. In fact, that price just might be the long-term happy-medium price that everyone can live with, much as $100 oil is today.

For investors and consumers alike, the future is clear: Demand and therefore the price for natural gas is likely to head higher over the longer term. That's quite positive for everyone involved, especially smart companies like Vanguard that are getting in early on the natural gas revolution. 

Another smart company leading the natural gas revolution is this little-known stock. It holds the key to the explosive profit power of the coming "no-choice fuel revolution." All the details are inside an exclusive report from The Motley Fool. Click here for the full story!

The article The Future of Natural Gas in 2 Slides originally appeared on Fool.com.

Fool contributor Matt DiLallo owns shares of SandRidge Energy and is also short September 2013 $5 puts on SandRidge Energy. The Motley Fool recommends Clean Energy Fuels and has options on Chesapeake Energy. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

1 Great Dividend You Can Buy Right Now

$
0
0

Filed under:

Dividend stocks are everywhere, but many just downright stink. In some cases, the business model is in serious jeopardy, or the dividend itself isn't sustainable. In others, the dividend is so low, it's not even worth the paper your dividend check is printed on. A solid dividend strikes the right balance of growth, value, and sustainability.

Today, and one day each week for the rest of the year, we're going to look at one dividend-paying company that you can put in your portfolio for the long term without too much concern. This isn't to say that these stocks don't share the same macro risks that other companies have, but they are a step above your common grade of dividend stock. Check out last week's selection.

This week, we'll turn our attention to our bellies and look at why Mondelez International could be the perfect stock for growth and income-seeking investors.

Source: gfpeck, Flickr.


The great dilemma
Let's face it: Not too many of us follow the "eat your vegetables" rule all too well, so it really shouldn't come as a surprise that snack foods have been a bright source of growth for food producers over the past few years. To take advantage of this growth, and to make the company more transparent for investors -- which often tends to unlock shareholder value -- Mondelez International was spun off from Kraft Foods in September 2012, separating its U.S.-based and slower growth Kraft business from the potentially faster overseas growth in its Mondelez division.

Overall, it sounds pretty straightforward -- that Kraft would be the slow-but-steady low-growth company that dividend investors sit on, while Mondelez would pour on the growth. But, of course, it hasn't been nearly that easy.

One of the biggest challenges for Mondelez has been uncooperative foreign currencies, which, when translated back into dollars, actually reduces how much Mondelez is bringing in. Based on Mondelez's second-quarter results, the company delivered an adjusted EPS of $0.71; however, it also faced a negative-$0.05 headwind related solely to currency translation. Mondelez isn't alone, either. Kellogg , the cereal and snack maker, stuck by its full-year EPS guidance when it released its second-quarter results, but it also upped its estimate for negative foreign currency translation impact by $0.07 to $0.09 for the year.

Foreign currency translation isn't the only concern. Competition among snack-food companies is increasing by leaps and bounds outside the United States - so much so that activist investor Nelson Peltz, the head of Trian Fund Management, suggested that PepsiCo purchase Mondelez and spin off its beverage operations. The idea would make a lot of sense given the increased levels of competition between the two companies, but PepsiCo doesn't appear keen on the idea

The Mondelez advantage
So if currency translation is an earnings drag and competition is increasing, why buy Mondelez? The answer to that question relates back to why Mondelez was spun off in the first place: emerging-markets exposure.

Shareholders should be more than willing to deal with a few pennies in negative foreign currency translation if it gives them the opportunity to jump aboard some very recognizable brand names -- Oreo, Cadbury, and Nabisco among them -- in rapidly growing emerging-market countries such as China, Russia, and Brazil. Revenue from emerging markets, led by the BRIC countries, jumped 9.7% sequentially in its second-quarter results. Furthermore, the company's Power Brands segment (Oreo, Cadbury, Chips Ahoy!, and Stride gum, to name a few) collectively grew by 7.9% which is double the company's average growth rate.

Where I think Mondelez offers its greatest advantage is in its Latin American and Eastern Europe/Middle East operations. Latin American revenue was pretty much flat in its latest quarter, yet its Power Brands grew by 14% in the region from the previous year. Eastern Europe and the Middle East, however, was its most robust growth region, with net revenue rising 7.7% and Power Brands gaining 15.6%.

This brings me to another key point for why Mondelez is an intriguing buy: organic growth! Mondelez isn't trying to scoop up another company every six months to boost its top line overseas -- it's doing it almost entirely from organic growth. Mondelez has practically perfected passing along price increases (there's a tongue twister for you!) to overseas consumers as food inflation rises while being able to fall back on the worldwide power of its brand-name products as justification for the increase. With solid pricing power, all Mondelez has to do is provide a good mix of snacks and beverages on supermarket shelves to make its top and bottom lines grow.

Show me the money, Mondelez
I know what you're probably thinking: "Kraft Foods is the dividend play here!" If we look at this from a pure yield standpoint, then yes, it is. However, if you would like your dividend stocks to show signs of growth so your share price has a shot at increasing along with your dividend, then Mondelez sure looks like the better choice of the two.

To begin with, Mondelez does a phenomenal job of taking care of its shareholders. Announced during the second quarter, Mondelez bolstered its share-repurchase program from just $1.2 billion to a whopping $6 billion through 2016. To put this in a different context, based on Mondelez's closing price on Friday, the company could repurchase about 195.6 million shares of its own stock -- roughly 11% of its outstanding share count -- and drop its forward P/E of 17.8 down below 16. Mondelez is making it very clear that boosting shareholder value is important to this management team.

Where Mondelez can really tack on value, though, is through its dividend. As you'll see, the big drop-off last year relates solely to the spinoff:


Source: Nasdaq.com.
*Assumes payout of $0.14/quarter for remainder of 2013.

Even during the Great Recession of 2009, Mondelez/Kraft was able to maintain its dividend despite the financial catastrophe that was unfolding around them. Also in its second quarter, Mondelez announced that it would boost its payout by 8%, or $0.01, to $0.14 going forward. The new projected yield based on its revised payout is 1.8%.

Foolish roundup
With Mondelez, growth and income investors are getting the entire package. They're getting exposure to rapidly growing emerging-market economies from a snack food and beverage perspective; they have well-recognized brand names to help buoy cash flow and allow Mondelez to pass along price increases with relative ease; and they have a company that may buy back up to $6 billion of its own shares through 2016 with a payout ratio of less than 33%, making dividend growth all but a certainty. I don't know about you, but that sounds like a tasty recipe for a great dividend stock to me!

Why should you love dividend stocks so much? Because they can make you rich -- it's as simple as that. While they don't garner the notability of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

Why should you love dividend stocks so much? Because they can make you rich -- it's as simple as that. While they don't garner the notability of high-flying growth stocks, they're also less likely to crash and burn. And over the long term, the compounding effect of the quarterly payouts, as well as their growth, adds up faster than most investors imagine. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

The article 1 Great Dividend You Can Buy Right Now originally appeared on Fool.com.

Fool contributor Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong. The Motley Fool owns shares of, and recommends PepsiCo. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

These Jobs Are Just Waiting to Be Filled

$
0
0

Filed under:

Photo credit: Flickr/photologue_np.

This year, oil and gas companies operating in the Marcellus and Utica Shale plan to hire at least 4,000 new employees. Available jobs range from engineering and construction to operations and maintenance, as well as positions in environmental health, safety, and administration. The problem is that these companies are often looking for qualified candidates, which are tough to find as so few have the technical experience these companies desire.


The good news is that because of the competition for qualified candidates, many companies are now looking to hire and train more local candidates. In fact, last year 96% of the new hires in the Marcellus and Utica were local candidates, as fewer experienced oil-field professionals are looking to relocate because of the oil and gas boom elsewhere in the United States. This is really good news for those looking for a job in the booming energy industry.

One company that's aggressively hiring in the region is Nuverra Environmental Solutions . The company was caught flat-footed last quarter as business grew faster than it expected. That situation forced the company to subcontract some of its work out, which hurt its profits. Now the company, according to CEO Mark Johnsrud, is "aggressively recruiting and hiring staff needed to expand our operations and meet the increased demands of our services." Anecdotally, I can attest to this. On a recent trip I saw a big billboard sponsored by the company that said it was hiring drivers for its water recycling business. (For those interested, Nuverra's career website is here.)

Another critical skill the energy industry requires is welding. According to the Bureau of Labor Statistics, the employment of welders is expected to grow by 15% from 2010 to 2020. In fact, both direct and indirect welding jobs currently account for about 2 million jobs, or about 10% of the country's manufacturing workforce.

Oilfield service companies such as Weatherford and Halliburton are among the many companies in search of welders. The operations of both companies span the globe. Weatherford employs more than 58,000 in over 100 countries, while Halliburton has more than 75,000 employees spread around 80 countries. Both have solid long-term growth opportunities both here in the U.S. and abroad. (For those specifically interested in a welding career at either of these two oilfield service giants or one of the many other companies hiring welders, click here.)

A sign of a strong business or industry is one that's hiring. Currently, the oil and gas industry is one of the fastest growing in the country, thanks to the vast amounts of oil and gas now being unlocked with horizontal drilling and hydraulic fracturing. That means it's a great time to be not just a job seeker, but also an investor. The oil and gas sector really has the potential to be a very lucrative one for investors positioned to profit from this energy boom. 

It's hard to argue that record oil and natural gas production is revolutionizing the United States' energy position. In the process, it's giving you the opportunity to get in on the ground floor of something really special. To find out where to start, The Motley Fool is offering a comprehensive look at three energy companies set to soar during this transformation in the energy industry. To find out which three companies are spreading their wings, check out the special free report, "3 Stocks for the American Energy Bonanza." Don't miss out on this timely opportunity; click here to access your report -- it's absolutely free. 

The article These Jobs Are Just Waiting to Be Filled originally appeared on Fool.com.

Fool contributor Matt DiLallo owns shares of Nuverra Environmental Solutions. The Motley Fool recommends Halliburton, owns shares of Nuverra Environmental Solutions, and has options on Nuverra Environmental Solutions . Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments


4 Dividend Stocks Switching Up Your Energy Portfolio

$
0
0

Filed under:

Utilities have been busy this past week, making moves to maximize profit potential. With nuclear and coal closures accompanying expanded transmission projects, here's what you need to know to stay on top of your dividend stocks' latest moves.

Mission for transmission
AGL Resources
announced last Monday that its New Jersey regulators have given the thumbs-up to a $115 million natural gas infrastructure improvement project. The upgrades are expected to take four years to be completed, and an accompanying rate case request should cover construction costs. AGL also received approval two weeks ago for a $275 million Georgia natural gas project.

In the latest transmission news, Westar Energy got the go-ahead Thursday to spend $66 million on an electric transmission project to increase reliability and efficiency in the area. Kansas regulators approved the project, along with recovery costs for the three- to four-year project.


Although natural gas additions have been ramping up lately, transmission projects overall have attracted the attention of many utilities. Their "tollbooth" business model can provide steady income with low operational costs, a welcome relief from the volatile world of competitive energy generation.

Can coal and nuclear cut it?
Natural gas has been choking coal's competitiveness
, but environmental groups have their own agenda against this energy source. After extensive litigation, Duke Energy announced this week that it has reached an agreement with several major environmental groups over air permits at its Indiana Edwardsport coal-fired power plant.

Source: Duke Energy.

Generally speaking, the settlement puts in writing what Duke would probably be doing otherwise. It sets mandatory dates for coal retirement, provides opportunities for natural gas switchovers, and outlines the possibility for small-scale renewable power projects. The utility has already planned to retire 3,400 MW of coal-fired power generation, is eyeing new natural gas investments, and just bought one of the largest urban solar farms in California to add to its 100-plus MW of solar generating capacity.

Duke has also been opting out of proposed nuclear projects -- and it's not alone. Entergy announced this past week that it'll take a $240 million hit to put a Vermont nuclear facility into early retirement. The utility cited cheap natural gas prices, high operational costs, and a tough regulatory environment as reasons for its "extremely tough call."

Entergy's decision to pull the plug might seem counterintuitive, considering the company's $400 million in investments over the past decade and licensing approval through 2032, but nuclear power is an increasingly risky business. Uranium costs are headed higher as sourcing remains a tricky affair, and natural gas' stubbornly low prices are killing the competitive outlook for many baseload energies.

Stay current on electricity
The world of utilities is changing fast, and dividend stocks aren't the stable stalwarts they once were. Be sure to check back weekly for the latest on your portfolio's moves, and you'll be well on your way to electrifying earnings.

These utilities are switching up their investment portfolios to maximize dividend stock profits -- and you should be, too. With this in mind, our analysts sat down to identify the absolute best of the best when it comes to rock-solid dividend stocks, drawing up a list in this free report of nine that fit the bill. To discover the identities of these companies before the rest of the market catches on, you can download this valuable free report by simply clicking here now.

The article 4 Dividend Stocks Switching Up Your Energy Portfolio originally appeared on Fool.com.

Fool contributor Justin Loiseau has no position in any stocks mentioned. You can follow him on Twitter, @TMFJLo, and on Motley Fool CAPS, @TMFJLo. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Is Google About to Unleash the Next War in Tech?

$
0
0

Filed under:

Charles Baudelaire once said, "The greatest trick the devil ever pulled was convincing the world that he did not exist." Fast-forward 150 years or so, and consider that it may turn out that the greatest trick Google ever pulled was convincing the world that it was not a device company. Well, right up until it reminded us in resounding fashion that it was, in fact, a world-class device company.

When Google released Chromecast, the device was an immediate success, selling out and going on back order both from Google itself and also from Amazon.com and Best Buy. This has been a significant departure from some recent Google projects that have been glossed over as fun little experiments -- Project Loon, Google Glass, and even Google Fiber. Much of what was written about these projects was couched in the assumption that Google is a search company that builds stuff to support that effort. Despite reaching a global market share, according to IDC, of 79.3% with Android, the free nature of the OS means it's often overlooked.

While Chromebooks -- or ultraportables -- have become the fastest-growing segment of the PC market, again, they are often looked at as a quirky afterthought. I think that's exactly what Google wants, and exactly why you should be jumping on the bandwagon early. By the time it becomes obvious that Google is a legitimate threat to Apple and Samsung in devices, a big part of the stock's move may have already been missed.


Chromecast was just the beginning
While Chromecast has received some mixed reviews, some believe it has the potential to be a game-changer for the streaming industry. The device isn't perfect, but it is cheap, works easily, and is clearly in hot demand. Unlike Google Glass, which at $1,500 is drawing more press than consumer buzz, Chromecast is a seller.

Along these same lines, Google looks to be stealthily preparing to explode into the smart-watch world. GigaOm recently reported that Google had acquired WIMM Labs to drive its ability to enter the new product segment. The story also noted that the WIMM team was working with the Android development team, suggesting that Google is looking to move quickly to market rather than park the project in multi-year development mode. Samsung is expected to roll out its own smart watch on Sept. 4, and Google may be close on its heels.

In addition to making it an entrant in the new product segment, the WIMM acquisition demonstrates how seriously Google takes another coming trend in technology. With add-on devices such as smart watches, Glass, and other wearable tech, you should expect to see your smartphone become the hub through which many of these other devices draw support. In this context, the importance of the integration between the OS and the hardware becomes obvious -- suddenly, the acquisition of Motorola seems to make a little bit more sense. As the next wave in technology is ready to unfold, it seems clear that Google is more than ready.

For the past period, Apple has been the undisputed heavyweight in personal electronics, with Samsung recently emerging as the only real competitor. Google has successfully downplayed its efforts and not looked like a real threat to most. I think that's about to change and that getting in now has the potential to reap significant rewards over the near term. Apple and Samsung are positioned to respond, but as things stand, Google is a stock to include in your portfolio.

This war could take many shapes. The tech world has been thrown into chaos as the biggest titans invade one another's turf. At stake is the future of a trillion-dollar revolution: mobile. To find out which of these giants is set to dominate the next decade, we've created a free report called "Who Will Win the War Between the 5 Biggest Tech Stocks?" Inside, you'll find out which companies are set to dominate and give in-the-know investors an edge. To grab a copy of this report, simply click here -- it's free!

The article Is Google About to Unleash the Next War in Tech? originally appeared on Fool.com.

Fool contributor Doug Ehrman has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Amazon.com, Apple, and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Will Ford Ditch Microsoft and Cozy Up With Apple?

$
0
0

Filed under:

When Apple (Nasdaq: AAPL) announced iOS in the Car at its Worldwide Developer Conference in June, the company projected a slide with many of the world's most recognizable car company logos. All the companies on the slide were onboard with incorporating iOS in the Car functionality starting in 2014. 

Eddy Cue unveils iOS in the Car auto partners at this year's WWDC. 


One notable omission was Ford (NYSE: F), which led many to believe the company was content with its Sync entertainment system which is built on Microsoft's (Nasdaq: MSFT) an embedded Windows Automotive operating system. 

Yet, in a recent interview with GottaBe Mobile, Ford's director of Electrical and Electronic Systems said the company hadn't ruled out using iOS in the Car. Instead, they were still evaluating the system and weren't ready to commit to a 2014 launch. 

While Apple trails Android's smartphone global market share by a large amount, its much more popular in the United States where it has around 40% share of the market. With Ford receiving more than half of its sales from the United States and Apple being very dominant in the American market, it only makes sense the company would consider ditching a Microsoft system it has heavily invested in for something that has stronger ties with Apple. 

To see a discussion on the future of in-car entertainment and why Ford is wise to take iOS in the Car seriously, watch the video below. 

In order for Ford's stock to soar, a few critical things need to fall into place. In The Motley Fool's special free report entitled, "5 Secrets to Ford's Future" we outline the key factors every Ford investor needs to watch. Just click here now for your free report.

The article Will Ford Ditch Microsoft and Cozy Up With Apple? originally appeared on Fool.com.

Eric Bleeker, CFA has no position in any stocks mentioned. Jamal Carnette owns shares of Apple. Simon Erickson owns shares of Apple and Microsoft. The Motley Fool recommends Apple and Ford. The Motley Fool owns shares of Apple, Ford, and Microsoft. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Do These 5 Locations Hold the Keys to American Energy Independence?

$
0
0

Filed under:

As the crisis in Syria reaches the boiling point, sending oil higher, it's time to rethink America's energy independence. It's estimated that 30% of the country's undiscovered oil and gas reserves lie within federal lands that are currently unavailable to oil and gas drillers. It's quite possible that there is even more oil than that just waiting to be discovered.

New technologies such as horizontal drilling, when combined with hydraulic fracturing, have unlocked shale oil reserves such as the Bakken and the Eagle Ford Shale. Top Bakken driller Continental Resources believes there are more than 24 billion barrels of recoverable crude oil equivalent in the Bakken, which, because of the oil-heavy nature of the formation, could double current proven oil reserves. Meanwhile, the discoverer of the Eagle Ford, EOG Resources , believes that it alone can recover 8% of the estimated 26.4 billion barrels of oil equivalent in place. These two massive oil discoveries have brought U.S. oil production to a 24-year high.

But it's not enough. The oil fields of yesteryear are declining even as companies such as ConocoPhillips are investing billions just to mitigate base decline in places like Alaska's North Slope. To reach energy independence, America needs to open up new areas to drilling.


The slideshow that follows overviews what we know about the five areas that are currently off limits to drilling but could hold the keys to our energy independence. One of the locations alone is believed to have the potential to displace the entire 1.35 million barrels of oil per day that the U.S. imports from Saudi Arabia. If unleashed, it represents OPEC's worst nightmare.

It's going to take more than one oil discovery or one company to bring about American energy independence. However, an exclusive, brand-new Motley Fool report reveals one company whose breakthrough technology really is becoming OPEC's Worst Nightmare. Just click here to uncover the name of this industry-leading stock, and join our nation's quest for energy independence and your chance at landslide profits.

The article Do These 5 Locations Hold the Keys to American Energy Independence? originally appeared on Fool.com.

Fool contributor Matt DiLallo owns shares of ConocoPhillips. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Is Apple's Expected New Tech a Huge Risk?

$
0
0

Filed under:

Anyone who's been paying attention to the chatter of late knows that Apple is expected to roll out the next generation of iPhones on Sept. 10, and that the new iPhone 5S is expected to include fingerprint scanning technology. Apple acquired AthenTec in 2012, and the acquisition is expected to lead to the inclusion of a fingerprint security feature in the iconic iPhone home button in the next model. If that's true, I believe there are three significant concerns Apple shareholders should be watching in the early weeks after the new devices begin to be reviewed and make it into the consumers' hands: Does it work, does anyone care, and is it being copied?

Does it work?
If you take for granted that the technology will be included in the iPhone 5S, the big question about the fingerprint scanner is whether it works as close to perfectly as people have come to expect. We all recall the barrage of bad press that came Apple's way when its Maps app was released and Google Maps was kicked off the iPhone, yet Apple's app was riddled with bugs. While some of these hiccups have been addressed, and Google has since released a Google Maps app for iOS, the entire exercise still stands, to me, as a step backwards. In my experience, Apple Maps still makes a fair number of mistakes, or at the least picks less desirable routes. The Google alternative works better, but because it isn't well integrated with the phone -- without several additional steps -- the end result is a less reliable experience.

I believe the bar is raised even further when we're talking about iPhone security. If the fingerprint scanner proves as temperamental as Siri -- the voice-activated digital assistant -- Apple could have a real problem. You can easily skip using Siri, or even Apple Maps, but if you become unable to access your phone at all, the technology has the potential to cause problems far beyond those Apple has ever seen. The logical belief is that Apple will find a way to let users reset their phones, should that happen; but if there's an easy workaround, then what kind of security does the technology really provide? I think it's admirable that Apple is reaching for progress, but the stakes seem to be very high.


Will anyone care?
I can't speak for the millions of people who use iPhones on a daily basis, but I've never any users lamenting that their iPhone was breached to their detriment. If the four-digit security function has proved insufficient for most users, it certainly has escaped the attention of the blogosphere. With that in mind, it seems improbable that anyone but those with a thirst for the latest and greatest would find a fingerprint scanner to be reason alone to buy an upgraded phone. The new device's other expected upgrades -- better camera, improved battery life, and greater speed -- must, therefore, be sufficient motivation.

Imitation is the purest form of flattery
If fingerprint scanning technology is well received on a broad basis, you should expect to see others copy it as quickly as they can. Where Apple has a distinct advantage is that because it controls both the device and the OS, it's probably better positioned to bring such technology to market. Would a competing offering come from Google through Android, or from Samsung in the Galaxy S series? In all probability, the two would have to work together. That's a definite advantage for Apple, particularly if it can expand the technology beyond smartphones.

The takeaway
While Apple is taking, in my opinion, a significant risk with fingerprint technology, the long-term benefits may be worthwhile. Imagine how appealing a similar feature might be for "iOS in the Car," for example. While you may have few concerns over the security of your smartphone, the security of your car is a different matter. Apple investors should pay careful attention to the reception that this feature gets over the weeks and months following the release, because it has the potential to be a huge immediate risk with substantial long-term rewards.

With the release of the new devices expected soon, you should remember that Apple has a history of cranking out revolutionary products and then creatively destroying them with something better. Read about the future of Apple in the free report, "Apple Will Destroy Its Greatest Product." Can Apple really disrupt its own iPhones and iPads? Find out by clicking here.

The article Is Apple's Expected New Tech a Huge Risk? originally appeared on Fool.com.

Fool contributor Doug Ehrman has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Apple and Google. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Who is the Right Person to Lead Microsoft After Ballmer?

$
0
0

Filed under:

Steve Ballmer's Microsoft (Nasdaq: MSFT) days are numbered. Within the next year, he'll be moving on from the company and the company will have just the third CEO of its 38 year history. 

Investors clearly wanted Ballmer to leave Microsoft; its shares jumped 7% on the news of his departure. However, the focus now shifts to what kind of leader Microsoft needs. 

In the video below Fool analysts Simon Erickson, Jamal Carnette, and Eric Bleeker discuss who the favorites are to talk over for Ballmer, and what kind of leader the company needs. Microsoft is deeply troubled in mobile and its online services, but also still reaps huge profits from Windows and its business unit and has seen big gains from its Server and Tools unit. Does Microsoft need a revolutionary leader, or someone to improve on the areas that are still working for the company?


The tech world has been thrown into chaos as the biggest titans invade one another's turf. At stake is the future of a trillion-dollar revolution: mobile. To find out which of these giants is set to dominate the next decade, we've created a free report called "Who Will Win the War Between the 5 Biggest Tech Stocks?" Inside, you'll find out which companies are set to dominate and give in-the-know investors an edge. To grab a copy of this report, simply click here -- it's free!


The article Who is the Right Person to Lead Microsoft After Ballmer? originally appeared on Fool.com.

Eric Bleeker, CFA has no position in any stocks mentioned. Jamal Carnette has no position in any stocks mentioned. Simon Erickson owns shares of Microsoft. The Motley Fool owns shares of Microsoft. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Markets Had a Terrible August; Buying Opportunities May Lie Ahead

$
0
0

Filed under:

This summer hasn't been very relaxing for investors, who have had to deal with the threat of tapering, rising interest rates, a number of new record highs on the major indexes, and, more recently, a possible military offensive in Syria. And with many market participants believing the Federal Reserve's stimulus tapering will begin in September, all while interest rates have been increasing and the Syrian conflict has escalated, August was the worst month for the major indexes thus far this year.

During the month, the Dow Jones Industrial Average lost 689 points, or 4.44%. The blue-chip average entered the month trading at 15,499 and hit an all-time high of 15,658 on Aug. 2. Now the index rests at 14,810. That performance follows a 3.5% gain in July -- proof that as quickly as gains can come on the market, they can disappear just as quickly.

The S&P 500 and the Nasdaq have taken a slightly different path from the Dow, but they've moved similar to each other the past two months. The S&P 500 started July at 1,606, ended the month at 1,685, hit a high of 1,709 Aug. 2, and closed August at 1,632. The Nasdaq, meanwhile, entered July at 3,403, closed the month at 3,626, peaked on Aug. 5 at 3,692, and closed the month at 3,589. The Nasdaq performed the best on a percentage basis, as it rose 6.55% in July and dropped only 1.02% in August, which still gives it a net gain of 5.46% over the past two months. The S&P 500, meanwhile, rose 4.91% in July and dropped 3.14% in August, leaving it with a two-month net gain of 1.61%.


And the Dow? It lost ground over the past two months, starting July at 14,909 and ending August at 14,810, a 99-point, or 0.66%, loss. August was only the second month this year it ended a month down, the last being in June, when it lost 1.36%. Back then, interest rates quickly rose in the last few weeks of May and through the majority of June as we first heard talk of tapering from the Federal Reserve members. I've written in the past about how big moves on the Dow this year have all related to days and months in which the Federal Reserve is meeting, having a press conference, or releasing meeting minutes.

I believe that for the remainder of 2013, we're bound to see more volatility in the market as the year ends and investors grow more concerned about tapering, or it actually begins and the markets react to the tearing off of the bandage. With that said, the sooner the Fed begins the tapering, the sooner the uncertainty and fear pertaining to it will begin to dissipate, which I believe will allow the markets to begin moving higher again.

But since we don't know when the tapering will start, or when the market will begin rising, average investors can only sit patiently and wait. And since you're just killing time until the next pop, if the market does continue to move lower, cheap buying opportunities may begin presenting themselves to those who are both patient and alert.

More Foolishness
The best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "
3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

The article Markets Had a Terrible August; Buying Opportunities May Lie Ahead originally appeared on Fool.com.

Fool contributor Matt Thalman has no position in any stocks mentioned. Check back Monday through Friday as Matt explains what caused the Dow's winners and losers of the day, and every Saturday for a weekly recap. Follow Matt on Twitter: @mthalman5513 The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments


Will You Soon Be Watching "The NFL On Google?"

$
0
0

Filed under:

This Labor Day weekend tens of millions will be travelling, enjoying the great outdoors. Yet, next weekend will see a different migration: to couches across America. Tens of millions will migrate back into their living rooms, whip up some nachos, and watch the daytime games on CBS and Fox. 

However the most zealous fans can currently watch almost any daytime game on DirecTV's (Nasdaq: DTV) Sunday Ticket. Its a package which costs hundreds of dollars, but has become a major draw for DirecTV. The company reportedly pays about a billion per year for Sunday Ticket, but still loses money on the package. Overall, even with direct losses piling up on Sunday Ticket, DirecTV has been happy with the package as a loss leader which encourages users to switch to broader satellite packages. 

Yet, that money losing package might get even more expensive in the future. The NFL confirmed commissioner Roger Goodell met with Google (Nasdaq: GOOG) last week, the presumed interest was Sunday Ticket. 


In the video below Fool analysts Eric Bleeker, Jamal Carnette, and Simon Erickson discuss the NFL's continued success stretching the value of its content. In addition, they look at how the NFL's continued negotiating clout with media companies could illustrate how sports have become the kingmaker in the new age of media where giant tech companies are looking to bring content online. 

The tech world has been thrown into chaos as the biggest titans invade one another's turf. At stake is the future of a trillion-dollar revolution: mobile. To find out which of these giants is set to dominate the next decade, we've created a free report called "Who Will Win the War Between the 5 Biggest Tech Stocks?" Inside, you'll find out which companies are set to dominate and give in-the-know investors an edge. To grab a copy of this report, simply click here -- it's free!

The article Will You Soon Be Watching "The NFL On Google?" originally appeared on Fool.com.

Eric Bleeker, CFA has no position in any stocks mentioned. Jamal Carnette has no position in any stocks mentioned. Simon Erickson has no position in any stocks mentioned. The Motley Fool recommends DirecTV and Google. The Motley Fool owns shares of Google. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Will These Oil Majors Regret Investing in Natural Gas?

$
0
0

Filed under:

Natural gas prices remain low in the United States, and that's meant pain for energy majors that have made domestic natural gas a strategic priority. This is evident in the recent struggles for ExxonMobil , which is suffering in the unfavorable environment for natural gas.

ExxonMobil famously purchased XTO Energy, the nation's largest holder of natural gas reserves, in 2009 for a staggering $41 billion, and the company now has egg on its face in light of the fact that its natural gas operations are serving as a drag on results.

Did ExxonMobil make a tragic mistake paying so much for XTO Energy? And, will other majors regret investing in natural gas as well?


Hindsight is 20/20

At the time of the acquisition, ExxonMobil appeared to make a savvy decision, positioning itself at the ground floor of what was predicted to be the great natural gas revolution in the United States.

Four years later, and ExxonMobil looks foolish for having paid such a huge amount of money for XTO. As Exxon readily admits, natural gas prices were roughly twice as high when the deal was completed as they are now.

At the company's annual shareholder meeting, Chief Executive Officer Rex Tillerson said "While we anticipated at the time of the merger that it would be non-accretive in the near-term, because we expected that natural gas prices had not yet bottomed out, they stayed low much longer than we expected".

Poor natural gas pricing in the United States, in addition to other headwinds such as lackluster refining results, combined to bring Exxon's second-quarter net income down 57% year over year. On a per-share basis, Exxon earned $1.55 in the quarter, representing the company's lower quarterly EPS number since September 2010.

To be fair, Exxon isn't the only oil major to have over-estimated the recovery in domestic natural gas prices. Competitor Chevron is also diving head-first into natural gas, noting that natural gas now comprises 22% of global energy demand.

The company estimates that as global populations expand, under-developed economies emerge, and the world's thirst for energy grows, natural gas will play an increasing role in the global energy mix. Chevron produced 5.07 billion cubic feet of natural gas per day in 2012, and will increase production exponentially over the next decade.

Specifically, the company points investors to its major projects in Australia and Africa, including the Gorgon Project which includes a 15 million metric-ton-per-year liquefied natural gas facility.

Importantly, Chevron's focus on natural gas outside the United States has spared it some of the pain currently afflicting ExxonMobil.

Chevron's own second-quarter results disappointed, but its 26% drop in quarterly profit wasn't as bad as Exxon's quarter. Moreover, Chevron shares have registered gains twice as big as Exxon's in the years since the XTO deal, rising 60% since the acquisition was announced versus 30% gains for Exxon.

Did Exxon make a $41 billion mistake?
In my estimation, only in the short term. U.S. natural gas prices remain at depressed levels, making Exxon's push into domestic natural gas look foolish today. But this seems like a simple matter of poor timing, rather than a mistake on the whole.

While $41 billion is certainly a huge sum of money, a juggernaut like ExxonMobil has the financial resources to endure, even if it did overpay for XTO Energy. And, the trend toward natural gas in America means that prices likely won't stay at such low levels for long. Sooner or later, as demand keeps rising, prices should follow suit.

Meanwhile, Chevron's focus on developing natural gas outside the United States means it's being spared some of the pain. For investors not willing to wait for the domestic natural gas turnaround, Chevron looks like a better near-term bet. But, the long-term vision of U.S. natural gas remains sound, in my opinion, and ExxonMobil should provide strong results for years to come.

Think the days of $100 oil are gone? Think again. In fact, the market is heading in that direction now. But for investors that are positioned to profit from the return of $100 oil, it can't come soon enough. To help investors get rich off of rising oil prices, our top analysts prepared a free report that reveals three stocks that are bound to soar as oil prices climb higher. To discover the identities of these stocks instantly, access your free report by clicking here now.

The article Will These Oil Majors Regret Investing in Natural Gas? originally appeared on Fool.com.

Robert Ciura has no position in any stocks mentioned. The Motley Fool recommends Chevron. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiov

$
0
0

Filed under:

Onglyza ® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial

  • SAVOR provides information on cardiovascular safety for Onglyza in the wake of past questions about cardiovascular safety of type 2 diabetes treatments
  • SAVOR is the largest cardiovascular outcomes trial to study a diverse population of type 2 diabetes patients at high risk for cardiovascular events
  • Onglyza did not meet the primary efficacy endpoint of superiority to placebo
  • In additional analyses, patients treated with Onglyza had improved glycemic control over two years

WILMINGTON, Del. & PRINCETON, N.J.--(BUSINESS WIRE)-- AstraZeneca (NYS: AZN) and Bristol-Myers Squibb Company (NYS: BMY) today announced the full results of the SAVOR clinical trial in 16,492 adult patients with type 2 diabetes at high risk for cardiovascular events. In this study, Onglyza® (saxagliptin) met the primary safety objective, demonstrating no increased risk for the primary composite endpoint of cardiovascular death, non-fatal myocardial infarction (MI) or non-fatal ischemic stroke, when added to a patient's current standard of care (with or without other anti-diabetic therapies), as compared to placebo. Onglyza did not meet the primary efficacy endpoint of superiority to placebo for the same composite endpoint. Patients treated with Onglyza experienced improved glycemic control and reduced development and progression of microalbuminuria over two years as assessed in exploratory analyses.

The major secondary composite endpoint of cardiovascular death, non-fatal MI, non-fatal ischemic stroke or hospitalization for heart failure, unstable angina or coronary revascularization was balanced across the two arms. One component of the composite secondary endpoint, hospitalization for heart failure, occurred more in the Onglyza group compared to placebo. Rates of pancreatitis were low and balanced between Onglyza and placebo. Overall rates of malignancy were balanced, and the observed rates of pancreatic cancer were lower in the Onglyza group than in the placebo group. More patients in the Onglyza group reported at least one hypoglycemic event compared to placebo. Results were presented today during a Hot Line session at the ESC Congress 2013 in Amsterdam, Netherlands, and published in The New England Journal of Medicine.


In the past, questions have been raised about the safety of many diabetes treatments, in particular regarding their impact on the risk of cardiovascular death, heart attack or stroke. Led by the academic research organizations TIMI Study Group and Hadassah University Medical Center and conducted at more than 700 sites worldwide, SAVOR (Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus) was a randomized, double-blind, placebo-controlled trial of 16,492 patients designed to evaluate the cardiovascular safety and efficacy of Onglyza (saxagliptin) in adults with type 2 diabetes at risk for cardiovascular death, heart attack and stroke, compared to placebo.

"Given the correlation between diabetes and cardiovascular complications, there is a need for thorough assessments of the cardiovascular risks among therapies that improve glycemic control," said Deepak L. Bhatt, MD, MPH, Senior Investigator of the TIMI Study Group, Brigham and Women's Hospital, and a Principal Investigator for the trial. "The results from SAVOR add important evidence to the overall body of data to further define the clinical profile of saxagliptin for the treatment of type 2 diabetes."

"No other DPP-4 inhibitor and few other anti-hyperglycemic agents have been studied as extensively as Onglyza to address the question of cardiovascular safety," said Brian Daniels, MD, senior vice president, Global Development and Medical Affairs, Research and Development, Bristol-Myers Squibb. "Bristol-Myers Squibb and AstraZeneca are dedicated to meeting needs of physicians and patients in diabetes care and helping to ensure a better understanding of the value of our medications."

"SAVOR is an important contribution to our knowledge of the safety of Onglyza in type 2 diabetes patients at an increased risk for cardiovascular events similar to those found in a real-world population," said Briggs Morrison, MD, executive vice president, Global Medicines Development, AstraZeneca. "In addition, the data on pancreatitis and pancreatic cancer in a study of more than 16,000 patients provide important and timely scientific information from a robust, randomized trial for the diabetes community."

Study Results

In the study, the primary composite endpoint of cardiovascular death, non-fatal MI or non-fatal ischemic stroke occurred in 613 patients (7.3%) in the Onglyza group vs. 609 patients (7.2%) in the placebo group (Hazard Ratio [HR]: 1.00; 95% Confidence Interval [CI]: 0.89, 1.12; non-inferiority p-value < 0.001; superiority p-value = 0.99). The major secondary endpoint, consisting of the primary composite endpoint and hospitalization for heart failure, unstable angina or coronary revascularization, occurred in 1,059 patients (12.8%) in the Onglyza (saxagliptin) group vs. 1,034 patients (12.4%) in the placebo group (HR: 1.02; 95% CI: 0.94, 1.11; p-value = 0.66). Hospitalization for heart failure, a component of this secondary composite endpoint, occurred at a greater rate in the Onglyza group (3.5%) than in the placebo group (2.8%) (HR: 1.27; 95% CI: 1.07, 1.51; p-value = 0.007). The pre-specified secondary endpoint of all-cause mortality occurred in 420 patients (4.9%) in the Onglyza group compared to 378 patients (4.2%) in the placebo group (HR: 1.11; 95% CI: 0.96, 1.27; p-value = 0.15).

Study physicians were allowed to actively manage patients' glucose through concomitant use of other anti-diabetic drugs and dose titration. Fewer patients in the Onglyza group required the addition or increase of any new anti-diabetic medication compared to placebo (1,938 patients [23.7%] vs. 2,385 patients [29.3%], respectively; HR: 0.77; 95% CI: 0.73, 0.82; p-value < 0.001) or the initiation of insulin therapy for more than three months (454 patients [5.5%] vs. 634 patients [7.8%], respectively; HR: 0.70; 95% CI: 0.62, 0.79; p-value < 0.001).Patients in the Onglyza group had greater reductions in blood sugar levels both from baseline and compared to those in the placebo group, with mean reductions in glycosylated hemoglobin (HbA1c) levels of 0.5% at two years of treatment in the Onglyza group vs. 0.2% in the placebo group (p-value < 0.001). More patients in the Onglyza group achieved or maintained goal HbA1c of less than seven percent compared to those in the placebo group at two years (40.0% vs. 30.3%; p-value < 0.001).

A total of 1,264 patients (15.3%) in the Onglyza group reported at least one hypoglycemic event compared to 1,104 (13.4%) in the placebo group (p-value < 0.001), which included patients with both major (177 patients [2.1%] vs. 140 patients [1.7%]; p-value = 0.047) and minor (1,172 patients [14.2%] vs. 1,028 patients [12.5%]; p-value = 0.002) events for the Onglyza and placebo groups, respectively. Hospitalization for hypoglycemia was infrequent and similar between groups (0.6% vs. 0.5%; p-value = 0.33).

Patients in the Onglyza group experienced reduced development and progression of microalbuminuria, and were more likely to have an improved albumin:creatinine ratio at two years (372 patients [11.1%] in the Onglyza group vs. 295 patients [9.2%] in the placebo group), and less likely to have a worsening ratio (414 patients [12.4%] in the Onglyza group vs. 457 patients [14.2%] in the placebo group), compared to placebo.

A number of pre-specified safety endpoints for diabetes treatments were evaluated (pancreatitis, cancer, liver abnormalities, renal abnormalities, thrombocytopenia, lymphocytopenia, infections, hypersensitivity or skin reactions, bone fractures and hypoglycemia).

All suspected cases of pancreatitis were independently reviewed and adjudicated by a committee of medical experts external to the sponsors and investigators. Pancreatitis occurred infrequently and the number of patients with acute or chronic pancreatitis was similar between the treatment groups (24 [0.3%] in the Onglyza (saxagliptin) group vs. 21 [0.3%], in the placebo group; p-value = 0.77). Definite/possible acute pancreatitis occurred in 22 patients (0.3%) in the Onglyza group vs. 16 patients (0.2%) in the placebo group (p-value = 0.42); definite acute pancreatitis in 17 patients (0.2%) vs. nine patients (0.1%) (p-value = 0.17); and chronic pancreatitis in two patients (< 0.1%) vs. six patients (0.1%) (p-value = 0.18), respectively. There were five cases of pancreatic cancer in the Onglyza group and 12 cases in the placebo group (p-value = 0.095). Renal abnormalities were observed more frequently in the Onglyza group compared to the placebo group (5.8% vs. 5.1%, respectively; p-value = 0.04). The incidence of the other pre-specified safety endpoints was balanced between the two groups.

Study Design

The study included 16,492 adult patients with type 2 diabetes, 8,280 of whom were randomized to receive Onglyza and 8,212 of whom were randomized to receive placebo. Recruitment included patients with type 2 diabetes and baseline HbA1c levels of 6.5% to 12% on any diabetes treatment including diet, insulin and/or oral therapy (excluding GLP-1 agonists and DPP-4 inhibitors) who were at elevated risk for cardiovascular events according to two categories:

  • Patients ≥ 40 years of age with established cardiovascular disease, defined as ischemic heart disease, peripheral vascular disease or ischemic stroke.
  • Males ≥ 55 years of age and females ≥ 60 years of age with at least one of the following risk factors: dyslipidemia, hypertension or current smoking, but without established cardiovascular disease.

Further grouping was based on renal function, including patients with normal/mild (eGFR > 50 mL/min), moderate (30 - 50 mL/min) or severe (eGFR < 30 mL/min) renal impairment.

The primary safety objective was to establish that the upper bound of the 95% confidence interval for the estimated risk ratio comparing the incidence of the composite endpoint (cardiovascular death, non-fatal MI or non-fatal ischemic stroke) observed with Onglyza to that observed in the placebo group was less than 1.3. The primary efficacy objective was to determine, as a superiority assessment, whether treatment with Onglyza compared to placebo when added to current background therapy would result in a reduction in the composite endpoint of cardiovascular death, non-fatal MI or non-fatal ischemic stroke in patients with type 2 diabetes. Secondary efficacy objectives included a reduction in the primary composite endpoint together with hospitalization for heart failure, coronary revascularization or unstable angina pectoris, and reduction of all-cause mortality. Secondary safety objectives included the evaluation of safety and tolerability by assessment of overall adverse events and adverse events of special interest.

Patients were randomized between May 2010 and December 2011. The median follow-up was 2.1 years and maximum follow-up was 2.9 years.

About Onglyza ® (saxagliptin)

As of September 2013, Onglyza is approved in 86 countries including those in the European Union, the United States, Canada, Mexico, India, Brazil and China.

Indication and Limitations of Use for Onglyza

Onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings.

Onglyza should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Onglyza has not been studied in patients with a history of pancreatitis.

Important Safety Information for Onglyza

Contraindications

  • History of a serious hypersensitivity reaction to Onglyza (e.g., anaphylaxis, angioedema, or exfoliative skin conditions)

Warnings and Precautions

  • Pancreatitis: There have been post-marketing reports of acute pancreatitis in patients taking Onglyza. After initiating Onglyza, observe patients carefully for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue Onglyza and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk of developing pancreatitis while using Onglyza.
  • Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin: When Onglyza was used in combination with a sulfonylurea or with insulin, medications known to cause hypoglycemia, the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin. Therefore, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia when used in combination with Onglyza.
  • Hypersensitivity Reactions: There have been post-marketing reports of serioushypersensitivity reactions in patients treated with Onglyza, including anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with Onglyza, with some reports occurring after the first dose. If a serious hypersensitivity reaction is suspected, discontinue Onglyza, assess for other potential causes for the event, and institute alternative treatment for diabetes. Use caution in patients with a history of angioedema to another DPP-4 inhibitor as it is unknown whether they will be predisposed to angioedema with Onglyza.
  • Macrovascular Outcomes: There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with Onglyza or any other antidiabetic drug.

Most Common Adverse Reactions

  • Most common adverse reactions reported in ≥5% of patients treated with Onglyza and more commonly than in patients treated with control were upper respiratory tract infection (7.7%, 7.6%), headache (7.5%, 5.2%), nasopharyngitis (6.9%, 4.0%) and urinary tract infection (6.8%, 6.1%).
  • When used as add-on combination therapy with a thiazolidinedione, the incidence of peripheral edema for Onglyza 2.5 mg, 5 mg, and placebo was 3.1%, 8.1% and 4.3%, respectively.
  • Confirmed hypoglycemia was reported more commonly in patients treated with Onglyza 2.5 mg and Onglyza 5 mg compared to placebo in the add-on to glyburide trial (2.4%, 0.8% and 0.7%, respectively), with Onglyza 5 mg compared to placebo in the add-on to insulin (with or without metformin) trial (5.3% and 3.3%, respectively),with Onglyza 2.5 mg compared to placebo in the renal impairment trial (4.7% and 3.5%, respectively), and with Onglyza 5 mg compared to placebo in the add-on to metformin plus sulfonylurea trial (1.6% and 0.0%, respectively).

Drug Interactions

Because ketoconazole, a strong CYP3A4/5 inhibitor, increased saxagliptin exposure, the dose of Onglyza should be limited to 2.5 mg when coadministered with a strong CYP3A4/5 inhibitor (eg, atazanavir, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin).

Use in Specific Populations

  • Patients with Renal Impairment: The dose of Onglyza is 2.5 mg once daily for patients with moderate or severe renal impairment, or with end-stage renal disease requiring hemodialysis (creatinine clearance [CrCl] ≤50 mL/min). Onglyza should be administered following hemodialysis. Onglyza has not been studied in patients undergoing peritoneal dialysis. Assessment of renal function is recommended prior to initiation of Onglyza and periodically thereafter.
  • Pregnant and Nursing Women: There are no adequate and well-controlled studies in pregnant women. Onglyza, like other antidiabetic medications, should be used during pregnancy only if clearly needed. It is not known whether saxagliptin is secreted in human milk. Because many drugs are secreted in human milk, caution should be exercised when Onglyza is administered to a nursing woman.
  • Pediatric Patients: Safety and effectiveness of Onglyza in pediatric patients have not been established.

Please click here for full U.S. Prescribing Information and Medication Guide for Onglyza ® (saxagliptin).

About Diabetes

In 2012, diabetes was estimated to affect more than 370 million people worldwide. The prevalence of diabetes is projected to reach more than 550 million by 2030. Type 2 diabetes accounts for approximately 90% to 95% of all cases of diagnosed diabetes in adults. Type 2 diabetes is a chronic disease characterized by insulin resistance and dysfunction of beta cells in the pancreas, leading to elevated glucose levels. Over time, this sustained hyperglycemia contributes to further progression of the disease. Significant unmet needs still exist, as many patients remain inadequately controlled on their current glucose-lowering regimen.

The major cause of death and complications in patients with type 2 diabetes is cardiovascular disease. As many as 80% of patients with type 2 diabetes will develop and possibly die from a cardiovascular event.

About the AstraZeneca / Bristol-Myers Squibb Diabetes Alliance

Dedicated to addressing the global burden of diabetes by advancing individualized patient care, AstraZeneca and Bristol-Myers Squibb are working in collaboration to research, develop and commercialize a versatile portfolio of innovative treatment options for diabetes and related metabolic disorders that aim to provide treatment effects beyond glucose control. Find out more about the Alliance and our commitment to meeting the needs of health care professionals and people with diabetes at www.astrazeneca.com or www.bms.com.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.com or follow us on Twitter at http://twitter.com/bmsnews.

AstraZeneca Cautionary Statement Regarding Forward-Looking Statement

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionary statement: This press release contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward looking statements reflect knowledge and information available at the date of preparation of this press release and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of patents, marketing exclusivity or trade marks, or the risk of failure to obtain patent protection; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; exchange rate fluctuations; the risk that R&D will not yield new products that achieve commercial success; the risk that strategic alliances and acquisitions will be unsuccessful; the impact of competition, price controls and price reductions; taxation risks; the risk of substantial product liability claims; the impact of any failure by third parties to supply materials or services; the risk of failure to manage a crisis; the risk of delay to new product launches; the difficulties of obtaining and maintaining regulatory approvals for products; the risk of failure to observe ongoing regulatory oversight; the risk that new products do not perform as we expect; the risk of environmental liabilities; the risks associated with conducting business in emerging markets; the risk of reputational damage; the risk of product counterfeiting; the risk of failure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; and the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation. Nothing in this press release should be construed as a profit forecast.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding product development. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Bristol-Myers Squibb's business, particularly those identified in the cautionary factors discussion in Bristol-Myers Squibb's Annual Report on Form 10-K for the year ended December 31, 2012, in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.



Media:
Bristol-Myers Squibb
Ken Dominski, 609-252-5251
ken.dominski@bms.com
or
AstraZeneca
Kirsten Evraire, 302-885-0435
kirsten.evraire@astrazeneca.com
or
Investors:
Bristol-Myers Squibb
Ranya Dajani, 609-252-5330
ranya.dajani@bms.com
or
Bristol-Myers Squibb
Ryan Asay, 609-252-5020
ryan.asay@bms.com
or
AstraZeneca
Kårl Hard, 44-20-7604-8123
karl.j.hard@astrazeneca.com

KEYWORDS:   United States  North America  Delaware  New Jersey

INDUSTRY KEYWORDS:

The article Onglyza® (saxagliptin) Achieves Primary Safety Endpoint, Demonstrating No Increased Risk for Cardiovascular Death, Heart Attack or Stroke in SAVOR Cardiovascular Outcomes Trial originally appeared on Fool.com.

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Oil in West Africa: A Mirror or a Mirage?

$
0
0

Filed under:

The pre-salt formation off the coast of Brazil has many speculators wondering whether there's a mirror-image formation on the West African side of the Atlantic, and several companies are taking a deeper look in hopes of finding massive quantities of oil opposite Brazil's Santos Basin. So far, the results of the exploration program haven't been as successful. BP's exploration program off the coast of Namibia was a dud, but companies looking further north have had more success.

Since this region is still very much in the exploration phase, investing here should be considered a rather high-risk play, but there are some other ways to invest in the region if you believe in its potential. Tune in to the following video, where fool.com contributor Tyler Crowe looks at whether the mirror theory has legs and how you can play this trend. 

With so much oil and gas activity going on in the U.S. today, though, you don't need to look beyond our borders to find companies that are soaring thanks to the shale boom. There are several companies in this space, but picking the right one for your portfolio can be like finding a needle in a pile of rusty needles. That's why we've put together a comprehensive look at three energy companies set to soar during this transformation in the energy industry. Let us help you discover which three companies are spreading their wings by checking out our special report, "3 Stocks for the American Energy Bonanza." Simply click here and we'll give you free access to this valuable report. 


The article Oil in West Africa: A Mirror or a Mirage? originally appeared on Fool.com.

Fool contributor Tyler Crowe has no position in any stocks mentioned. You can follow him at Fool.com under the handle TMFDirtyBird, on Google +, or on Twitter: @TylerCroweFool. The Motley Fool recommends Petrobras, Seadrill, Statoil, and Total. The Motley Fool owns shares of Seadrill and Transocean. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

 

Read | Permalink | Email this | Linking Blogs | Comments

Repurpose Leftovers and Savor the Savings -- Savings Experiment

$
0
0

Filed under: ,

Repurposing leftovers is a great way to save money while satisfying your taste buds -- you just have to use a little creativity in the kitchen. Here are a few great tips on how to take your leftovers from bland to grand.

You don't need a big budget to make a filling meal. For instance, if you have leftover pizza in the fridge, cut it into small squares and use it as the bread base for an exciting egg casserole or fritatta.

Extra mashed potatoes are surprisingly versatile. For one, you can make homemade gnocchi with them, just by adding egg yolks and flour. They're also an excellent flour substitute. Simply freeze the leftover mashed potatoes and you can use one part mash to two parts flour in almost any recipe.

If you have leftover rice, try mixing it in with pancake batter. Although it sounds a bit strange, the rice will actually expand the volume of your pancakes, and add a distinct flavor that goes well with jelly.

Pasta with potatoes and grated cheese in a casserole dishThose with a sweet tooth can create a healthy treat from ripe bananas. Just freeze the fruit for an hour, and then mash it up to create a silky version of ice cream.

Using these easy tips, you can create multiple meals without dipping too deep into your budget. Bon appetit!

 

Permalink | Email this | Linking Blogs | Comments

Viewing all 9760 articles
Browse latest View live




Latest Images